Preclinical studies demonstrated its dual renoprotective and atheroprotective effects in Apoe+ mice with STZ-induced diabetes, with NOX1 inhibition reducing atherosclerosis and NOX4 deletion unexpectedly increasing plaque area [19,20]. Here, NOX1 is linked to atherosclerosis.